Loading
companiesCompany
Greenwich LifeSciences
Greenwich LifeSciences is a Texas biotech running a phase 3 trial of GLSI-100, a HER2 peptide vaccine given after standard treatment to stop breast cancer coming back.
Also called: Greenwich LifeSciences, Inc.NASDAQ:GLSI
Overview
Greenwich LifeSciences develops GLSI-100, a combination of the HER2-derived peptide GP2 with the immune adjuvant GM-CSF, as an immunotherapy to prevent recurrence in HER2-positive breast cancer after surgery and trastuzumab. In a phase 2b trial, HER2-positive patients who completed the full vaccine course had no recurrences over five years. The phase 3 FLAMINGO-01 trial is enrolling HER2-positive patients with residual disease after neoadjuvant therapy.
Headquarters
Stafford, Texas, US
Scorecard
All companies#394of 1244 companies, score 9
- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:GLSI
Stage
Public
Founded
2006
Phase 3vaccine
GLSI-100 is an experimental cancer vaccine from Greenwich LifeSciences in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at HER2.